论文部分内容阅读
目的:观察地塞米松在肺纤维化过程中对胶原积聚的抑制作用,探讨地塞米松治疗肺纤维化的机理。方法:随机分为对照组、致伤组和治疗组,经气管内注射博莱霉素制备大鼠肺纤维化模型,通过腹腔注射地塞米松进行治疗,在肺纤维化形成过程的不同阶段测定肺组织胶原含量。结果:致伤组胶原含量在3、7、14、27d分别为:(26.59±0.62)mg,(34.24±0.48)mg,(37.06±0.19)mg,(31.79±0.11)mg,治疗组为:(24.99±0.05)mg,(31.65±0.63)mg,(30.56±0.59)mg,(28.38±0.19)mg,P<0.01。结论:地塞米松能够抑制肺纤维化因素导致的肺部正常组织的破坏及肺组织胶原的沉积,从而有效阻止肺纤维化的进展。
OBJECTIVE: To observe the inhibitory effect of dexamethasone on collagen accumulation in pulmonary fibrosis and to explore the mechanism of dexamethasone in treating pulmonary fibrosis. Methods: The rats were randomly divided into control group, injury group and treatment group. Bleomycin was injected intratracheally to prepare rat model of pulmonary fibrosis. The rats were treated by intraperitoneal injection of dexamethasone and were measured in different stages of pulmonary fibrosis Lung tissue collagen content. Results: The collagen content in the injured group was (26.59 ± 0.62) mg, (34.24 ± 0.48) mg, (37.06 ± 0.19) mg and (31.79 ± 0.11) mg on the 3, 7, (24.99 ± 0.05) mg, (31.65 ± 0.63) mg, (30.56 ± 0.59) mg and (28.38 ± 0.19) mg respectively, P <0.01. Conclusion: Dexamethasone can inhibit the destruction of normal lung tissue and the deposition of collagen in lung tissue caused by pulmonary fibrosis, which can effectively prevent the progression of pulmonary fibrosis.